TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Efficacy of DFPP in Patients With AAGN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a diagnosis of ANCA associated vasculitis(AAV), using criteria adapted from the disease definitions of the Chapel Hill consensus conference~* serum positive ANCA and the ANCA level ≥100 relative unit/ml~* with renal involvement and serum creatinine≥3 mg/dl~* written informed consent had been provided.~Exclusion Criteria:~* other secondary vasculitis~* anti-glomerular basement membrane(GBM) positive~* severe infection; hepatitis B antigenemia, anti- hepatitis C virus~* immunodeficiency; or immunoglobulin G(IgG)\<2g/l~* life threatening~* renal biopsy show globally sclerotic glomeruli\>60% and normal glomeruli\<10%~* need renal replacement therapy for more than 4w~* received large dose of methylprednisolone(MP),CTX,mycophenolate mofetil(MMF), plasmapheresis or intravenous immunoglobulin(IVIg) therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DFPP&CTX (Type: EXPERIMENTAL): double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP\&CTX)
- cyclophosphamide (Type: ACTIVE_COMPARATOR): cyclophosphamide(CTX) pulse therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Latent Tuberculosis in Socially Marginalised Citizens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reporting to be homeless (independent of whether the person has an official address) or regularly seeking homeless shelters or public institutions to supply basic needs~* LTBI defined by positive IGRA test~* Found plausible by study doctor that the person has been exposed to tuberculosis within 2 years~* Aged 18 years or older~Exclusion Criteria:~* Previously treated for tuberculosis~* Pregnant or breastfeeding~* Active tuberculosis (evaluated by chest x-ray and examination by a trained doctor)~* Unable to give informed consent~* Tested positive for LTBI as part of contact investigation where the index case has or is suspected to have INH of RIF resistant TB~* Known HIV on antiretroviral treatment~* Porphyria~* Known allergy to rifamycins or isoniazid~* Known epilepsy~* Known liver disease causing affected liver parameters (ALAT, alkaline phosphatase, bilirubin, INR)~* Any lab abnormality, disease, concomitant medication or condition that, in the opinion of the investigator, excludes a person from participating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RPT-INH (Type: EXPERIMENTAL): Participants treated with weekly rifapentine and isoniazid for twelve weeks.
- control (Type: ACTIVE_COMPARATOR): Participants treated with daily isoniazid for six months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vikings Fitness Playbook: A Family Based Lifestyle Modification Program for Overweight and Obese Youth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Survivor of childhood cancer for ≥5 years (N = 24) and no history of childhood cancer (N = 24)~* Age 8-16 years old at the time of consent~* BMI ≥ 85th percentile or waist circumference ≥ 85th percentile for age and gender~Exclusion Criteria:~* Exercise/physical activity contraindicated~* Initiation of a new drug therapy within the past 30 days prior to study commencement~* Current (within 3 months of study commencement) use of weight loss medication(s)~* History of weight loss surgery~* Obesity from a genetic cause (e.g., Prader-Willi)~* Central nervous system injury or severe neurological impairment~* Known systolic or diastolic dysfunction or heart failure

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Lifestyle Modification (Type: OTHER): Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Vitamin D Induction in Optic Neuritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Canadian residents~* Patients must be between age 18 and 45 years~* Patients must have a diagnosis of either a CIS or RRMS (according to McDonald criteria)~* Patients must have an EDSS of 5.5 or less~* Patients must demonstrate features of a first typical optic neuritis within 21 days of recruitment (or must initiate treatment by day 30)~* Patients must have a baseline 25(OH)D \< 80 nmol/L regardless of vitamin D3 supplementation~* Patients must have no contraindications to high-dose vitamin D supplementation~* Female patients must consent to use a reliable form of contraception (oral contraceptive pill, intrauterine device, barrier methods, abstinence) for the duration of the active treatment phase (first 90 days of where study drug provided) of the trial~* Patients must provide written informed consent.~Exclusion Criteria:~* Patients who have had a previous optic neuritis~* Patients with evidence of a non-inflammatory cause of optic neuropathy~* Patients with evidence of neuromyelitis optica spectrum disorder or NMOSD (i.e. bilateral optic neuritis, MRI evidence of longitudinally enhancing lesions involving the optic nerves (involving three or more segments of the optic nerve), and/or involving the optic chiasm, and optic tracts~* Patients with a 25(OH)D \> 80 nmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- High-Dose Vitamin D Treatment Group (Type: EXPERIMENTAL): Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)
- Placebo/Standard Vitamin D3 Group (Type: PLACEBO_COMPARATOR): Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of Lightweight Ambulatory Oxygen Systems for Individuals With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently in a stable phase of COPD, defined as having had no disease exacerbation within the 4 weeks prior to study entry~* Ambulatory~* Forced expiratory volume in one second (FEV1) less than or equal to 60% of predicted value at screening~* Ratio of FEV1 and forced vital capacity (FEV1/FVC) less than or equal to 65% of predicted value at screening~* Currently receiving long-term oxygen therapy (LTOT)~* Partial pressure of oxygen in arterial blood (PaO2) less than 60 torr~Exclusion Criteria:~* Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, left-sided heart failure, peripheral vascular disease, exertional angina, complex arrhythmias, severe dependent edema, ischemic changes on stress electrocardiogram that would be contraindications for unrestricted ambulation or the 6-minute walk test)~* Orthopedic impairments that would limit ambulation~* Participation in the active phase of pulmonary rehabilitation within the 3 months prior to study entry~* Neurologic impairments (e.g., Parkinson's disease or a stroke) or mental states (e.g., senile dementia) that would limit independent ambulation~* Neoplastic disease that is anticipated to influence survival~* Currently receiving lightweight ambulatory oxygen therapy~* Inability to maintain an oxygen saturation of 92% at rest with 4 liter/minute of continuous oxygen flow and during exercise with an oxygen conserver setting of 6 utilizing a nasal cannula~* Currently a smoker~* Sleep apnea if it is characterized primarily as central sleep apnea syndrome (whether being treated or not) OR if it is known or suspected obstructive sleep apnea that has existed for at least 2 months and has not received stable treatment (stable treatment modes include positive airway pressure therapies or dental orthotic/mandibular positioning devices); individuals with diagnosed obstructive sleep apnea must have a body mass index less than or equal to 30 kg/m2 to be eligible for this study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E-Cylinder (Type: ACTIVE_COMPARATOR): 22-lb E-cylinder towed on a cart
- Lightweight Cylinder (Type: ACTIVE_COMPARATOR): 3.6-lb lightweight cylinder that can be carried

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ECM and Blood Components for Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or Type 2 diabetes, and/or venous insufficiency to the affected leg~* Ulcer has been present between 12 and 52 weeks~* Ulcer is less than 40 cm2 in area~Exclusion Criteria:~* Less than 18 years of age~* Pregnant or planning to become pregnant during the study period~* Simultaneously participating in another investigational drug or device study~* Unable or unwilling to comply with the weekly study follow-up schedule or off-loading regimen~* Patient or legal representative refuses to sign the EC-approved informed consent form~* Known allergy to pig or porcine products~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ECM in Saline (Type: EXPERIMENTAL): None
- Blood Products (Type: ACTIVE_COMPARATOR): None
- ECM in Blood Products (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and female greater than 18 years of age~2. Positive stool C. difficile cytotoxin assay and/or biopsy evidence of Pseudomembranous Colitis (PMC) at onset of illness~3. Current history of severe, relapsing CDAD or Current history of severe, refractory CDAD~4. A score of 6 or 7 on the C.Diff Severity and Prognosis Score (CDSPS) scale27,28,29,30 OR failure to respond (as identified by a score of 4 or more on the CDSPS scale below) to any of the following: a 4-day or more course of oral or IV metronidazole 500 mg po TID or QID; or to a 4-day course of oral vancomycin 125-500 mg po Q6 hours; or to a 4-day course of vancomycin enemas; or failure to respond to a 4-day course of combination therapy of oral vancomycin 125-500 mg po Q6 hours and IV metronidazole 500mg IV Q8 or Q6 hours and/or vancomycin enemas.~CDSPS SCALE (each item is scored as one point for a 7 point maximum total)~1. underlying immunosuppression/chronic medical condition~2. altered or depressed mental status as defined by medical chart documentation~3. abdominal pain and/or distention~4. WBC \> 20,000 or \< 1,500 and/or bandemia \> 10%~5. hypoalbuminemia (\<3 mg/dL)~6. ascites (clinically or per CT scan findings per medical chart)~7. abnormal CT scan findings per medical chart -~Exclusion Criteria:~1. Pregnant or lactating women~2. Selective IgA deficiency~3. Hypersensitivity to immune globulin, human albumin, or thimerosal -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IVIG (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer~* Breast cancer from ER+ primary that is seen on other imaging tests; tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease~* At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging~* Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES~* Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; selected treatments may be part of experimental treatment protocols for which the patient would be separately consented~* Patients must be willing to undergo serial imaging procedures~* Patients must agree to allow access to clinical records regarding response to treatment and long term follow up~Exclusion Criteria:~* An inability to lie still for the tests~* Individuals weighing more than 300 lb; (this is the weight limit of the scanner table)~* Pregnant or lactating; women of childbearing potential with either a positive or no pregnancy test at baseline are excluded~* Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication)~* Use of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent \< 6 weeks or chemotherapy \< 3 weeks prior to imaging scan~* Unwillingness or inability to give informed consent~* Uncontrolled diabetes mellitus (fasting glucose \> 200 mg/dL)~* Adult patients who require monitored anesthesia for PET scanning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (F-18 FES PET/CT) (Type: EXPERIMENTAL): Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Colorectal liver metastases deemed resectable on three-phase computed tomography (CT)-scan of the liver~* No evidence of extrahepatic disease on CT chest and abdomen and possible fluorodeoxyglucose (FDG)-PET (if part of surgical work-up)~* No evidence of local recurrence or second primary colorectal tumor on colonoscopy or colonography~* Primary colorectal tumor radically removed~* Informed consent~Exclusion Criteria:~* Pregnancy~* Recent chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast~* Radiologic or pathologic evidence that the cancer is metastatic or locally advanced (a T4 tumor and stage IIIB/IIIC disease) and not curable by local measures, such as radiation or surgery~* Positive status for human epidermal growth factor receptor 2~* Measurable disease as per Response Evaluation Criteria In Solid Tumors guidelines~* Karnofsky performance status of 70 to 100~* Life expectancy of at least 3 months~Exclusion Criteria:~* Prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine~* Common Terminology Criteria Grade 2 or greater neuropathy~* Inadequate hematologic, hepatic, or renal function~* Known prior severe hypersensitivity reactions to agents containing Cremophor® EL or known hypersensitivity or prior intolerance to fluoropyrimidine~* Known or suspected dihydropyrimidine dehydrogenase deficiency~* More than 3 prior chemotherapy regimens in the metastatic setting~* Prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg (Type: EXPERIMENTAL): Dose Level 1
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg (Type: EXPERIMENTAL): Dose Level 2
- Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg (Type: EXPERIMENTAL): Dose Level 3
- Ixabepilone + Lapatinib + Capecitabine (Type: EXPERIMENTAL): Triplet Combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years, male or female~* Diagnosis: multiple myeloma undergoing Autologous Stem Cell Transplantation (SCT)~* Planning to receive conditioning chemotherapy (Melphalan) for autologous stem cell transplantation and standard prophylactic antibiotics treatment.~* Can drink 200ml of mannitol and agrees to undergo stool, urine, and blood checks 3 times during the study.~* Agrees and able to take the investigational products or placebo starting from the day of completing conditioning therapy for a total of 4 weeks~Exclusion Criteria:~* Patients with history of inflammatory bowel disease will be excluded from the study.~* Patients with prior GI tract surgical (small or large bowel) resections~* The concurrent presence of systemic light chain amyloidosis~* Subject has known allergy or intolerance to beef or to any ingredient used in the product~* Women who are pregnant, breast-feeding and of child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: SBI + Placebo (Type: ACTIVE_COMPARATOR): Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
- Group B: Colesevelam + Placebo (Type: ACTIVE_COMPARATOR): Colesevelam 1.875 g + Placebo twice per day
- Group C: Colesevelam + SBI (Type: ACTIVE_COMPARATOR): Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
- Group D: Double Placebo (Type: PLACEBO_COMPARATOR): Double placebo twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues